Philip Marder

1.1k citations

45 papers · 929 indexed · h-index 17

Immunology and Allergy top 5%
- Cell Adhesion Molecules Research 6
Immunology top 10%
- Immune Response and Inflammation 9
- T-cell and B-cell Immunology 4
Oncology top 10%
Toxicology top 10%
Molecular Biology
- Glycosylation and Glycoproteins Research 4
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 9
Physiology
- Asthma and respiratory diseases 9
Hematology
- Platelet Disorders and Treatments 4
Surgery
- Heparin-Induced Thrombocytopenia and Thrombosis 3

Co-authors: Lisa J. Green Stephen M. Spaethe Christopher A. Slapak Jon R. Schmidtke Larry L. Froelich Richard M. Schultz Eric R. Prossnitz Alexis Traynor‐Kaplan
Cited by: Immunology and Allergy Immunology Oncology
Journals: The Journal of Immunology (3 papers)Clinical Cancer Research (1 paper)Biochemical and Biophysical Research Communications (1 paper)
Partner nations: United States Netherlands Singapore

In The Last Decade

Philip Marder

45 papers receiving 889 citations

Peers

Countries citing papers authored by Philip Marder

Since Specialization

Citations

This map shows the geographic impact of Philip Marder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Marder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Marder more than expected).

Fields of papers citing papers by Philip Marder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Marder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Marder. The network helps show where Philip Marder may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Philip Marder, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Philip Marder Line = papers co-authored together Philip Marder links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Flow cytometry in drug discovery and development Wiley eBooks ·Virginia Litwin,Philip Marder	2011	4
2	Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells11Abbreviations: MDR, multidrug resistance (resistant); Pgp,P-glycoprotein; Rh123, rhodamine 123; DNR, daunorubicin; TMBY,trimethoxybenzoylyohimbine; CsA, cyclosporin A; VER, verapamilhydrochloride; and MFI, mean fluorescence intensity. Biochemical Pharmacology ·Lisa J. Green,Philip Marder,Christopher A. Slapak	2001	57
3	In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone (1-34) fragment Bone ·Dinesh Stanislaus,Xiaonan Yang,J. Liang,Jami M. T. Wolfe,R. L. Cain,J.E. Onyia,N Falla,Philip Marder,Joseph P. Bidwell,S. W. QUEENER,Janet M. Hock	2000	55
4	The Discovery of LY293111, a Novel, Potent and Orally Active Leukotriene B4 Receptor Antagonist of the Biphenylphenol Class Advances in experimental medicine and biology ·Michael J. Sofia,Paul E. Floreancig,N. Bach,Stephen Baker,K. LeRoi. Nelson,J. Scott Sawyer,Ronald F. Baldwin,Sandra L. Cockerham,J H Fleisch,Larry L. Froelich,William T. Jackson,Philip Marder,C. R. Roman,D L Saussy,Steven A. Silbaugh,Stephen M. Spaethe,Peter W. Stengel	1997	7
5	Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis Cancer Chemotherapy and Pharmacology ·John L. Tonkinson,Philip Marder,Sherri L. Andis,Richard M. Schultz,Lynn S. Gossett,Chuan Shih,L G Mendelsohn	1997	72
6	The regulation of CD11b integrin levels on human blood leukocytes and leukotriene B4-stimulated skin by a specific leukotriene B4 receptor antagonist (LY293111) Biochemical Pharmacology ·Jpa Van Pelt,E.M.G.J. de Jong,P.E.J. van Erp,Malcolm I. Mitchell,Philip Marder,Stephen M. Spaethe,Candida Aem van Hooijdonk,A.L.A. Kuijpers,P C van de Kerkhof	1997	20
7	The effects of LY293111Na, a leukotriene B4 receptor antagonist, on the pulmonary neutrophilia and CD11b expression caused by inhalation of a leukotriene B4 aerosol in rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics ·David L. Allen,Wherly P. Hoffman,Philip Marder,Michele Matchett,Paula A. Leiter,D. Abbott,Rodrigo Wolff	1996	11
8	Inhibition of ex vivo neutrophil activation by oral LY293111, a novel leukotriene B4 receptor antagonist British Journal of Clinical Pharmacology ·Philip Marder,Stephen M. Spaethe,Larry L. Froelich,Benito J. Cerimele,B H Petersen,T. Tanner,R. A. Lucas	1996	16
9	Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist Biochemical Pharmacology ·Philip Marder,J. Scott Sawyer,Larry L. Froelich,Larry Mann,Stephen M. Spaethe	1995	43
10	Investigation of neutrophil signal transduction using a specific inhibitor of phosphatidylinositol 3-kinase. The Journal of Immunology ·Chris J. Vlahos,William F. Matter,Raymond F. Brown,Alexis Traynor‐Kaplan,P G Heyworth,Eric R. Prossnitz,R D Ye,Philip Marder,J A Schelm,Kimberly J. Rothfuss,(unknown),(unknown)	1995	162
11	Total synthesis and biological properties of novel antineoplastic (chloromethyl)furanoindolines: an asymmetric hydroboration mediated synthesis of the alkylation subunits Journal of Medicinal Chemistry ·F. MOHAMADI,M. M. SPEES,G. S. STATEN,Philip Marder,J. K. KIPKA,David A. Johnson,Dale L. Boger,Hamideh Zarrinmayeh	1994	40
12	o-Phenylphenols: potent and orally active leukotriene B4 receptor antagonists Journal of Medicinal Chemistry ·Michael J. Sofia,Paul E. Floreancig,Nicholas J. Bach,Stephen Baker,Sandra L. Cockerham,Jerome H. Fleisch,Larry L. Froelich,William T. Jackson,Philip Marder	1993	8
13	Ligand Interactions with the RGD Recognition Site Alter Binding of GPIIb-IIIa Reactive Monoclonal Antibody to Human Platelets Biochemical and Biophysical Research Communications ·Philip Marder	1993	2
14	Flow cytometric evaluation of the effects of leukotriene B4 receptor antagonists (LY255283 and SC-41930) on calcium mobilization and integrin expression of activated human neutrophils Prostaglandins Leukotrienes and Essential Fatty Acids ·Philip Marder,Richard M. Schultz,Stephen M. Spaethe,Michael J. Sofia,David K. Herron	1992	16
15	Effects of two leukotriene B4 (LTB4) receptor antagonists (LY255283 and SC-41930) on LTB4-induced human neutrophil adhesion and superoxide production Prostaglandins Leukotrienes and Essential Fatty Acids ·Richard M. Schultz,Philip Marder,Stephen M. Spaethe,David K. Herron,Michael J. Sofia	1991	10
16	Selective cloning of hybridoma cells for enhanced immunoglobulin production using flow cytometric cell sorting and automated laser nephelometry Cytometry ·Philip Marder,Ronald S. Maciak,Rebecca L. Fouts,Robert S. Baker,James J. Starling	1990	29
17	Characterization of the Human Tumor and Normal Tissue Reactivity of the KS1/4 Monoclonal Antibody Hybridoma ·Thomas F. Bumol,Philip Marder,Sonja V. Deherdt,Michael J. Borowitz,L D Apelgren	1988	56
18	Reactivation of class II antigen expression in murine macrophage hybrids. The Journal of Immunology ·Steven H. Zuckerman,Robert D. Schreiber,Philip Marder	1988	7
19	Cyclosporin a inhibits helper/inducer surface antigen expression on activated human lymphocytes International Journal of Immunopharmacology ·Philip Marder,Jon R. Schmidtke	1985	8
20	Potentiation of Leu 11+ natural cytotoxicity by human interleukin 2 Clinical Immunology and Immunopathology ·Edwin W. Ades,Ann Hinson,Philip Marder,L D Butler	1984	7

About Philip Marder

Philip Marder is a scholar working on Immunology and Allergy, Immunology and Hematology, having authored 45 papers that have together received 929 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (9 papers), Immune Response and Inflammation (9 papers), Asthma and respiratory diseases (9 papers), Cell Adhesion Molecules Research (6 papers), Glycosylation and Glycoproteins Research (4 papers), Platelet Disorders and Treatments (4 papers), T-cell and B-cell Immunology (4 papers) and Heparin-Induced Thrombocytopenia and Thrombosis (3 papers). The work is most often cited by research in Immunology and Allergy (97 citations), Immunology (265 citations) and Oncology (237 citations). Philip Marder has collaborated with scholars based in United States, Netherlands and Singapore. Frequent co-authors include Lisa J. Green, Stephen M. Spaethe, Christopher A. Slapak, Jon R. Schmidtke, Larry L. Froelich, Richard M. Schultz, Eric R. Prossnitz, Alexis Traynor‐Kaplan, L D Apelgren and Raymond F. Brown. Their work appears in journals such as The Journal of Immunology, Clinical Cancer Research and Biochemical and Biophysical Research Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact